Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by ontheDLon Aug 30, 2011 5:42pm
664 Views
Post# 18995294

Morning Coffee- CANACCORD WEALTH MANAGEMENT

Morning Coffee- CANACCORD WEALTH MANAGEMENT – Canadian and U.S. Comments for Tuesday August 30, 2011 - Sleeman shines. Yukon-focused precious metals company Golden Predator announced results from 11 additional diamond drill holes from the recently discovered Sleeman Zone as part of the ongoing drill program at its flagship Brewery Creek Project.Management stated that all 11 holes encountered significant mineralization. Highlight intersections included: hole BC11- 249 with 27.8 m of 1.86 g/t gold and 116.0 g/t silver from a depth of 67.1 m, including 6.4 m of 4.09 g/t gold and 429.9 g/t silver; and hole BC11-251 with 29.3 m of 1.76 g/t gold and 16.0 g/t silver from a depth of 95.7 m. Management noted that drilling continues to expand the newly discovered Sleeman Zone with mineralization now established for more than 200 m along strike and over 190 m down dip. Adding that significant silver values continue to be reported throughout the Sleeman drilling with numerous intervals in excess of 30 g/t, further enhancing the project's potential economics. Also on Monday, Golden Predator announced that it has begun a diamond drill program on the AJ target at its Antimony Project, which is located 25 km north of the company's Brewery Creek Project. The current drill program at AJ will follow up on mineralization discovered by the company in 2009 highlighted by 12.45 g/t gold over 4.88 m including 28.81 g/t gold over 2.45 m from hole number AJ09-017.
Bullboard Posts